CN101516335B - 苯并咪唑基吡啶基醚的制剂 - Google Patents

苯并咪唑基吡啶基醚的制剂 Download PDF

Info

Publication number
CN101516335B
CN101516335B CN200780035017.9A CN200780035017A CN101516335B CN 101516335 B CN101516335 B CN 101516335B CN 200780035017 A CN200780035017 A CN 200780035017A CN 101516335 B CN101516335 B CN 101516335B
Authority
CN
China
Prior art keywords
preparation
formulation
mixture
compound
polyoxyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780035017.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101516335A (zh
Inventor
A·哈沙什
S·里奇
K·林
P·沈
A·奥哈玛菲
R·古尔拉帕里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101516335A publication Critical patent/CN101516335A/zh
Application granted granted Critical
Publication of CN101516335B publication Critical patent/CN101516335B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200780035017.9A 2006-07-21 2007-07-20 苯并咪唑基吡啶基醚的制剂 Expired - Fee Related CN101516335B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83271506P 2006-07-21 2006-07-21
US60/832,715 2006-07-21
PCT/US2007/016469 WO2008011154A2 (en) 2006-07-21 2007-07-20 Formulations for benzimidazolyl pyridyl ethers

Publications (2)

Publication Number Publication Date
CN101516335A CN101516335A (zh) 2009-08-26
CN101516335B true CN101516335B (zh) 2014-01-08

Family

ID=38819293

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780035017.9A Expired - Fee Related CN101516335B (zh) 2006-07-21 2007-07-20 苯并咪唑基吡啶基醚的制剂

Country Status (20)

Country Link
US (1) US8455662B2 (enExample)
EP (1) EP2046292B1 (enExample)
JP (1) JP2009544617A (enExample)
KR (1) KR20090033904A (enExample)
CN (1) CN101516335B (enExample)
AT (1) ATE459338T1 (enExample)
AU (1) AU2007275634B2 (enExample)
BR (1) BRPI0715423A2 (enExample)
CA (1) CA2657346A1 (enExample)
CY (1) CY1110037T1 (enExample)
DE (1) DE602007005139D1 (enExample)
DK (1) DK2046292T3 (enExample)
ES (1) ES2340631T3 (enExample)
HR (1) HRP20100293T1 (enExample)
MX (1) MX2009000770A (enExample)
PL (1) PL2046292T3 (enExample)
PT (1) PT2046292E (enExample)
RU (2) RU2452469C2 (enExample)
SI (1) SI2046292T1 (enExample)
WO (1) WO2008011154A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
CA2678335A1 (en) 2007-03-02 2008-11-20 Novartis Ag Solid forms of a raf kinase inhibitor
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2012006081A1 (en) * 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulation of kinase inhibitors
JP5923499B2 (ja) 2010-06-30 2016-05-24 ベラステム インコーポレイテッド キナーゼインヒビターの合成および使用
CN102336740B (zh) * 2010-07-27 2013-07-24 中国科学院上海药物研究所 一类咪唑类化合物及其用途
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121714A (zh) * 1994-02-28 1996-05-01 一洋药品株式会社 新的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物
CN1649863A (zh) * 2002-03-09 2005-08-03 阿斯特拉曾尼卡有限公司 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
CA2256109A1 (en) 1996-05-23 1997-11-27 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6391683B1 (en) * 2000-06-21 2002-05-21 Siliconware Precision Industries Co., Ltd. Flip-chip semiconductor package structure and process for fabricating the same
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US20040131670A1 (en) * 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20050082192A1 (en) * 2002-06-17 2005-04-21 Eric Smarr End cap support for jumbo rolls of material
US7846959B2 (en) * 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US20100231394A1 (en) * 2009-03-11 2010-09-16 Bobby Eugene Finchum Carbon monoxide detection and dissipation apparatus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121714A (zh) * 1994-02-28 1996-05-01 一洋药品株式会社 新的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物
CN1649863A (zh) * 2002-03-09 2005-08-03 阿斯特拉曾尼卡有限公司 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物

Also Published As

Publication number Publication date
ATE459338T1 (de) 2010-03-15
CA2657346A1 (en) 2008-01-24
US8455662B2 (en) 2013-06-04
RU2009105819A (ru) 2010-08-27
AU2007275634B2 (en) 2011-01-20
JP2009544617A (ja) 2009-12-17
EP2046292B1 (en) 2010-03-03
EP2046292A2 (en) 2009-04-15
SI2046292T1 (sl) 2010-06-30
CY1110037T1 (el) 2015-01-14
ES2340631T3 (es) 2010-06-07
HRP20100293T1 (hr) 2010-06-30
CN101516335A (zh) 2009-08-26
US20100040677A1 (en) 2010-02-18
RU2452469C2 (ru) 2012-06-10
PT2046292E (pt) 2010-04-26
WO2008011154A3 (en) 2008-06-26
KR20090033904A (ko) 2009-04-06
BRPI0715423A2 (pt) 2013-07-02
AU2007275634A1 (en) 2008-01-24
RU2012107218A (ru) 2013-09-10
DK2046292T3 (da) 2010-06-07
DE602007005139D1 (de) 2010-04-15
MX2009000770A (es) 2009-01-28
PL2046292T3 (pl) 2010-08-31
WO2008011154A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
CN101516335B (zh) 苯并咪唑基吡啶基醚的制剂
JP6932746B2 (ja) エンザルタミドの製剤
JP2009544617A5 (enExample)
ES2262517T3 (es) Composicion oral antifugal que contiene itraconazol y procedimiento para su preparacion.
AU2014210103B2 (en) Pharmaceutical composition with improved bioavailability
ES2737955T3 (es) Complejos de acetato de abiraterona, proceso para la preparación de los mismos y composiciones farmacéuticas que los contienen
JP5583119B2 (ja) インドリノン誘導体の即時放出のための医薬投薬形態
KR101454086B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
WO2000000179A1 (en) Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof
CN102470103A (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
CN101516870B (zh) 苯并咪唑基吡啶基醚的盐以及其制剂
JP2019163327A (ja) 三種混合製剤
CA3160834C (en) Amorphous pharmaceutical compositions of abiraterone acetate
WO2016086950A1 (en) Pharmaceutical composition containing non-lipophilic hydrophobic drug and process for the preparation thereof
US20200155583A1 (en) Solid oral formulations of amphotericin b
TW201338780A (zh) 藥物組成及其製備方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140108

Termination date: 20140720

EXPY Termination of patent right or utility model